Education
About Us
Working with TipRanks
Follow Us
Immunic (IMUX)
NASDAQ:IMUX
IMUX Stock Chart & Stats
$1.11
-$0.01(-1.34%)
At close: 4:00 PM EST
$1.11
-$0.01(-1.34%)
Day’s Range― - ―
52-Week Range$0.51 - $1.35
Previous CloseN/A
Volume261.21K
Average Volume (3M)4.65M
Market Cap
$144.82M
Enterprise Value$94.74M
Total Cash (Recent Filing)$15.48M
Total Debt (Recent Filing)$684.00K
Price to Earnings (P/E)―
Beta1.02
Next Earnings
May 07, 2026EPS Estimate
-0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.10
Shares Outstanding130,464,830
10 Day Avg. Volume3,319,060
30 Day Avg. Volume4,646,211
Financial Highlights & Ratios
PEG Ratio0.23
Price to Book (P/B)-124.52
Price to Sales (P/S)0.00
P/FCF Ratio-9.67
Enterprise Value/Market Cap0.65
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-2.26K
Enterprise Value/Ebitda-0.96
Forecast
1Y Price Target
$3.67Price Target Upside230.63% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.34
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Mechanism Of Action And Potential Disease ModificationVidofludimus calcium's dual action—DHODH inhibition combined with Nurr1 activation—may both reduce relapses and provide neuroprotective effects, supporting the possibility of true disease modification versus existing oral therapies.
Pivotal Phase III ReadoutsFully enrolled Phase III ENSURE-1 and ENSURE-2 trials could produce pivotal placebo-controlled readouts that determine vidofludimus calcium's regulatory prospects and commercial positioning.
Supportive Phase II Data And Antiviral SignalPhase II CALLIPER and EMPhASIS results showing MRI lesion reductions and encouraging effects in non-active progressive MS, together with observed antiviral activity against Epstein-Barr virus, strengthen the clinical case for use in difficult-to-treat patient populations.
Bears Say
Competitive Differentiation UncertaintyUncertainty about how vidofludimus calcium will clearly differentiate from many existing and emerging oral MS therapies may constrain physician adoption and market share even if trial signals remain positive.
Financing And Dilution RiskA persistent financing overhang and limited internal funding could necessitate additional capital raises or partnerships, creating dilution risk and downward pressure on the stock.
Valuation Sensitivity To AssumptionsAnalyst price target reductions after adjusting share count and launch assumptions highlight downside valuation risk if commercial uptake or penetration falls short of expectations.
Immunic News
IMUX FAQ
What was Immunic’s price range in the past 12 months?
Immunic lowest stock price was $0.51 and its highest was $1.35 in the past 12 months.
What is Immunic’s market cap?
Immunic’s market cap is $144.82M.
When is Immunic’s upcoming earnings report date?
Immunic’s upcoming earnings report date is May 07, 2026 which is in 61 days.
How were Immunic’s earnings last quarter?
Immunic released its earnings results on Feb 26, 2026. The company reported -$0.1 earnings per share for the quarter, missing the consensus estimate of -$0.09 by -$0.01.
Is Immunic overvalued?
According to Wall Street analysts Immunic’s price is currently Undervalued.
Does Immunic pay dividends?
Immunic does not currently pay dividends.
What is Immunic’s EPS estimate?
Immunic’s EPS estimate is -0.09.
How many shares outstanding does Immunic have?
Immunic has 130,464,830 shares outstanding.
What happened to Immunic’s price movement after its last earnings report?
Immunic reported an EPS of -$0.1 in its last earnings report, missing expectations of -$0.09. Following the earnings report the stock price went up 4.066%.
Which hedge fund is a major shareholder of Immunic?
Currently, no hedge funds are holding shares in IMUX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Immunic Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$3.67 (230.63% Upside)
$3.67 (230.63% Upside)
Blogger Sentiment
Bullish
IMUX Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 1.8M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.6%
Last 30 Days ▲ 4.2%
Last 30 Days ▲ 4.2%
News Sentiment
Very Bullish
Bullish news 80%
Bearish news 20%
Bearish news 20%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-5.12%
12-Months-Change
Fundamentals
Return on Equity
-1653.15%
Trailing 12-Months
Asset Growth
-41.15%
Trailing 12-Months
Company Description
Immunic
Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and other chronic inflammatory and autoimmune diseases, as well as to treat coronavirus disease. The company is also developing IMU-935, an inverse agonist of ROR?t; and IMU-856 for the restoration of the intestinal barrier function in patients suffering from diseases, such as inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor induced colitis, and other intestinal barrier function diseases. Immunic, Inc. is headquartered in New York, New York.
IMUX Stock 12 Month Forecast
Average Price Target
$3.67
▲(230.63% Upside)
Technical Analysis
aTyr Pharma
―
vTv Therapeutics
―
NRX Pharmaceuticals
―
Equillium
―
Werewolf Therapeutics
―
Ownership Overview
1.05% Insiders
3.96% Mutual Funds
0.14% Other Institutional Investors
91.23% Public Companies and Individual Investors